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ABSTRACT
Nucleoside analog-associated sensory neuropathy (NRTI-SN) attributed to stavudine, didanosine, or zal-
citabine (the dNRTIs) and distal sensory polyneuropathy (DSP) attributed to HIV are clinically indistin-
guishable. As inflammatory cytokines are involved in DSP, we addressed a role for inflammation in NRTI-
SN by determining the alleles of immune-related genes carried by patients with and without NRTI-SN.
Demographic details associated with risk of various neuropathies were included in the analysis. Alleles of 14
polymorphisms in 10 genes were determined in Australian HIV patients with definite NRTI-SN (symptom on-
set 6 months after first dNRTI exposure, n  16), NRTI-SN-resistant patients (no neuropathy despite 6
months on dNRTIs, n  20), patients with late onset NRTI-SN (neuropathy onset after 6 months of dNR-
TIs, n  19), and HIV-negative controls. Carriage of TNFA-1031*2 was highest in NRTI-SN patients, sug-
gesting potentiation of NRTI-SN. Carriage of IL12B (3 UTR)*2 was higher in NRTI-SN-resistant patients
than controls or NRTI-SN patients, suggesting a protective role. BAT1 (intron 10)*2 was more common in
NRTI-SN than resistant patients, but neither group differed from controls. This marks the conserved HLA-
A1, B8, DR3 haplotype. Of the demographic details considered, increasing height was associated with NRTI-
SN risk. A model including cytokine genotype and height predicted NRTI-SN status (p  0.0001, R2  0.54).
Late onset NRTI-SN patients clustered genetically with NRTI-SN-resistant patients, so these patients may be
genetically “protected.” In addition to patient height, cytokine genotype influenced NRTI-SN risk following
dNRTI exposure, suggesting inflammation contributes to NRTI-SN.
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INTRODUCTION
ANTIRETROVIRAL THERAPY (ART) has dramatically improvedlife expectancy with HIV infection,1 but toxic effects from
ART are evident in a subset of patients. Nucleoside analog-as-
sociated sensory neuropathy (NRTI-SN) is a common, dis-
abling, and typically irreversible toxicity of ART.2 High rates
of neuropathy are now reported from HIV treatment centers
throughout the world. The debilitating nature of NRTI-SN, its
high prevalence, and the limited efficacy of current treatments2
make this a clinically important problem.
NRTI-SN is clinically and histologically similar to distal sen-
sory polyneuropathy (DSP) caused by HIV itself. The only dis-
tinguishing feature is the temporal relationship between symp-
tom onset and exposure to particular nucleoside analog reverse
transcriptase inhibitors (NRTIs): zalcitabine (ddC), stavudine
(d4T), or didanosine (ddI) (denoted dNRTI) in NRTI-SN.2
Thus, dNRTI exposure is both a diagnostic marker and a pri-
mary risk factor for NRTI-SN. Although ddC is no longer in
clinical use, d4T continues to be included in first line ART in
many countries to avoid the higher cost and risk of anemia with
AZT.
NRTI-SN does not affect all patients treated with a dNRTI,
and most cases occur in the first 6 months of exposure.2 The de-
mographic and treatment predispositions described only partly
predict the individual’s NRTI-SN risk.2–4 The following lines of
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evidence suggest that genetic markers of host inflammatory re-
sponses may further refine a prediction of risk for NRTI-SN:
1. Host inflammatory responses can influence disease in a
broad setting of HIV infection. Rates of other complications
of HIV treatment5 including HIV-associated neurological
diseases are associated with cytokine genotype, notably al-
leles of TNFA.6
2. Several findings suggest a role for the host inflammatory re-
sponse in DSP, which is phenotypically similar to NRTI-
SN. An accumulation of activated macrophages in the ner-
vous system is a feature of all HIV-associated neurological
disease and can occur despite advanced immunosuppres-
sion.7,8 Increased levels of tumor necrosis factor (TNF)-
and reduced levels of interleukin (IL)-4 have been docu-
mented in peripheral nerves from six patients with DSP, but
not neuropathy-free individuals with HIV.9
3. A role for host inflammatory responses has been established
in lipodystrophy, another important complication of anti-
retroviral therapy.10 Abacavir hypersensitivity reactions in
white patients associate with carriage of an MHC haplotype
that includes HLA-B57.11
4. Polymorphisms in the hemochromatosis (HFE) gene asso-
ciate with risk of NRTI-SN.12 HFE lies on chromosome 6
and may be in linkage disequilibrium with alleles of other
genes in the MHC.
Here we addressed known polymorphisms in immune-re-
lated genes as determinants of NRTI-SN risk following dNRTI
exposure. Several genes studied lie in the MHC. These include
HSPA1B,13 TNFA, and BAT1. A polymorphism in intron 10 of
BAT1 provides a specific marker of the central MHC region
characteristic of the 8.1 haplotype (HLA-A1, B8, DR3), which
is associated with multiple immunopathological diseases.14,15
Demographic details, including patient height,16 have previ-
ously been associated with risk of various neuropathies. These
were included to obtain an optimal model for the prediction of
NRTI-SN risk with dNRTI exposure.
MATERIALS AND METHODS
Patients were selected from the Australian arm of a cohort
study examining the effects of HIV and its treatment on the pe-
ripheral nervous system.3 Individuals with any established risk
factor for neuropathy other than HIV infection or antiretroviral
exposure (including diabetes mellitus or a history of excessive
alcohol consumption) were excluded from the parent study. All
subjects were adults (18 years) with HIV infection attending
the Alfred Hospital Infectious Diseases Clinic in Melbourne,
Australia. All but two were white. Detailed demographic, treat-
ment, and clinical details were available on all subjects. Con-
trols were retired donors from the West Australian Bone Mar-
row Registry (95% white and presumed to be HIV negative,
n  79–270). This work was approved by the local Human Re-
search and Ethics Committee, and was conducted in accordance
with the Helsinki Declaration of 1975, as revised in 2000. All
patients gave written, informed consent to participate.
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TABLE 1. CARRIAGE OF TNFA AND IL12B ALLELES DISTINGUISHES PATIENTS BY NRTI-SN STATUSa
NRTI-SN resistant (n  20) Definite NRTI-SN (n  16)
A 1,1 1,2 2,2 1,1 1,2 2,2 p valueb
IL1B3953 50.c 44.4 5.6 50 50 0 1.0
IL6-174 40 50 10 37 63 0 0.88
IL10R11112d 42.1 36.8 21.1 37.5 50 12.5 0.78
IL18-607 30 45 25 25 62.5 12.5 0.74
HSPA1B1267 45 45 10 37.5 43.8 18.7 0.65
IL18-137 35 55 10 43.8 50 6.2 0.59
IL1A4845 60 35 5 50 43.8 6.2 0.55
IL10-592 60 40 0 50 43.8 6.2 0.55
IL10-1082 25 45 30 12.5 62.5 25 0.35
IL4-589 80 20 0 62.5 25 12.5 0.24
BAT1 (intron 10) 85 15 0 62.5 37.5 0 0.12
TNFA-308 80 20 0 56.3 37.5 6.2 0.12
IL12B (3 UTR) 45 50 5 81.3 18.7 0 0.03
TNFA-1031 60 20 20 18.8 75 6.2 0.01
B Odds ratio 95% confidence interval p value
BAT1 (intron 10) 16.50 01.2–227. 0.036
TNFA-1031 13.80 01.4–134. 0.024
IL12B (3 UTR) 0.16 0.02–1.10 0.056
aCritical alleles were identified by univariate analysis (A) and confirmed by multivariate analysis (B, p  0.001 overall).
b2 test comparing carriage of allele 2 between NRTI-SN patients and those resistant to NRTI-SN.
cAllele frequencies are shown as percentages.
dNot available for one ATN-resistant individual.
Assessment of neuropathy
Patients were assessed for peripheral neuropathy using the
AIDS Clinical Trials Group Brief Peripheral Neuropathy
Screen (ACTG BPNS).17 Neuropathy was defined as present
if the individual had at least one of the lower limb neuropathic
symptoms elicited using this tool (pain, aching or burning,
pins and needles, or numbness) together with at least one of
absent ankle reflexes or reduced vibration sense at the great
toe (vibration of a 128-Hz tuning fork felt for 10 s or less).
Patients were defined as neuropathy free if they had no lower
limb neuropathic symptoms and had normal ankle reflexes and
normal vibration sense at the great toe bilaterally. All patients
from the cohort who met one of the following criteria were
included:
1. Definite NRTI-SN: Patients with neuropathy (symptoms and
signs on the ACTG BPNS) in whom symptom onset oc-
curred within the first 6 months of exposure to their first
dNRTI.
2. NRTI-SN resistant: Patients who remain neuropathy free (no
symptoms and no signs on the ACTG BPNS) despite at least
6 months of cumulative exposure to at least one dNRTI.
3. Late onset NRTI-SN: Patients with neuropathy (symptoms
and signs on the ACTG BPNS) where symptom onset oc-
curred after 6 months of dNRTI exposure.
DNA extraction and genotyping
Patient peripheral blood mononuclear cells were obtained by
Ficoll density gradient centrifugation and DNA was extracted
using the QIAamp DNA Mini Kit (Qiagen Inc., Chatsworth,
CA) according to the manufacturer’s protocols.
Genomic DNA was screened using established PCR restric-
tion fragment length polymorphism (RFLP) assays to determine
the alleles carried at IL1B3953 and BAT1 (intron 10)
(rs9281523), IL6-174,5,18 IL12B (3 UTR),19 TNFA-308
(rs1800629),20 HSPA1B1267,13 IL4-589, TNFA-1031
(rs1799964), and IL10-592.21 IL10-1082 and IL10R11112 
alleles were determined by PCR-confronting two pair
primers.22,23 Other assays were based on FAM and VIC-labeled
probes and Universal PCR Master Mix (Taqman, Applied
Biosystems) in 5 l reactions. Assay IDs were C_9546471_10
for IL1A4845 (rs17561), C_2408543_10 for IL18-137
(rs187238), and C_2890460_10 for IL18-607 (rs1956518).
Control samples carrying (1,1), (1,2), and (2,2) were included
in all runs.
Data analysis
Statistical analyses were performed using Stata 9.2 (Stata-
Corp, USA). To accommodate small numbers with the (2,2)
genotype at most loci, genotypes were grouped as (1,1) versus
(1,2 or 2,2) in all analyses. Associations between alleles and
NRTI-SN status (and with controls) were assessed individually
using 2 tests. Demographic details of patients with and with-
out NRTI-SN were compared using 2 or unpaired t tests, as
appropriate. Multivariate analyses were undertaken using mul-
tiple case–control logistic regression with a reverse selection
procedure.
RESULTS
Associations between genotype and a definite
diagnosis of NRTI-SN
Univariate analyses of genotype and NRTI-SN status (resis-
tant versus definite; Table 1A) showed increased carriage of
TNFA-1031*2 (p  0.01) and reduced carriage of IL12B (3
UTR)*2 (p  0.03) in patients with definite NRTI-SN. Weak
associations were noted with BAT1 (intron 10)*2 and TNFA-
308*2, where these alleles were in linkage disequilibrium. The
multivariate analysis included all alleles where p  0.3, but
BAT1 (intron 10) was used (rather than TNFA-308) because it
is a specific marker of TNF gene block of the HLA-A1, B8,
DR3 haplotype. Some individuals with TNFA-308*2 carry
other haplotypes.15 A model including BAT1 (intron 10),
TNFA-1031, and IL12B (3 UTR) was highly significant over-
all (p  0.001; Table 1B).
Comparison with HIV-negative control populations
Frequencies of alleles associated with NRTI-SN in the mul-
tivariate analysis were compared with data from population-
based control populations of similar ethnicity (Table 2). Car-
riage of TNFA-1031*2 was higher in patients with NRTI-SN
(compared with controls and NRTI-SN-resistant patients), so
we associate this allele with susceptibility to NRTI-SN. In con-
trast, IL12B (3 UTR)*2 is overrepresented among NRTI-SN-
resistant patients (compared with controls and patients with
NRTI-SN), so we associate this allele with resistance to NRTI-
SN. Although BAT1 (intron 10)*2 tended to occur more often
in NRTI-SN patients (compared with controls and NRTI-SN-
resistant patients), the differences were not significant.
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TABLE 2. COMPARISONS WITH CONTROL DONORS ASSOCIATED IL12B (3 UTR)*2 
WITH RESISTANCE AND TNFA-1031*2 WITH SUSCEPTIBILITY TO NRTI-SN
NRTI-SN Definite
Controls resistant pa NRTI-SN pa
BAT1 (intron 10) 63/270b (23%) 4/20 (20%) 0.73 6/16 (37%) 0.20
TNFA-1031 24/79 (33%) 8/20 (40%) 0.41 13/16 (81%) 0.0001
IL12B (3 UTR) 84/256 (33%) 11/20 (55%) 0.044 3/16 (19%) 0.24
aRelative to control population (2 test).
bProportions of donors carrying allele 2.
Inclusion of patients with late onset NRTI-SN in 
the model
Patients defined as having late onset NRTI-SN (n  19) had
neuropathy, but their symptoms began after 6 months of expo-
sure to a dNRTI (mean time on a dNRTI prior to NRTI-SN symp-
tom onset was 29 months, range 7–54 months). These subjects
were similar to those with NRTI-SN in terms of age when tested,
age at first exposure to a dNRTI, and nadir CD4 T cell count (t
test, p  0.05; data not shown). We addressed whether they are
genetically predisposed to NRTI-SN or are moderately protected
from this complication of dNRTI therapy (Table 3A). When late
onset NRTI-SN patients were grouped with patients with definite
NRTI-SN in the logistic regression analysis, the optimal model
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TABLE 3. DEVELOPMENT OF NEUROPATHY AFTER 6 MONTHS ON A dNRTI 
MAY NOT REFLECT GENETIC SUSCEPTIBILITY TO NRTI-SNa
NRTI-SN resistant Late onset NRTI-SN
(n  20) (n  19) NRTI-SN (n  16)
A 1,1 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2
TNFA-308 80.b 20 0 90 10 0 56 37 6.2
BAT1 (intron 10) 85 15 0 90 10 0 62 37 0
TNFA-1031 60 20 20 63 21 16 19 75 6.2
IL12B (3 UTR) 45 50 5 68 25 5.3 81 19 0
IL4-589 80 20 0 79 21 0 62 25 12
B Odds ratiob 95% confidence interval p value
BAT1 (intron 10) 8.1 1.3–50.2 0.02
TNFA-1031 9.3 1.7–50.9 0.01
IL12B (3 UTR) 0.38 0.08–1.87 0.20
aAlleles identified in Table 1 (shown in A) were evaluated in multivariate analyses where patients with late onset NRTI-SN
were grouped with those who were NRTI-SN resistant (B, p  0.001 overall).
bAllele frequencies are shown as percentages.
TABLE 4. ANALYSIS OF DEMOGRAPHIC DETAILSa
NRTI-SN resistant/
late onset NRTI-SN Definite NRTI-SN
A patients patients p value
Age at first dNRTI (mean  SD) 42.3  10.3 44.3  8.1 0.50b
Plasma lactate 2.03  0.7 2.00  0.6 0.75b
Nadir CD4 T cell count (cells/l) 134  107 185  187 0.22b
Height (cm) 173  6.8 182  7.2 0.0001b
Years HIV positive at first dNRTI 4.8  3.7 4.6  4.4 0.88b
Current HIV viral load 13279  27225 14000  31790 0.93b
(copies/ml)
Male gender 97% 100% 0.51c
Hepatitis C antibody positive 13% 8% 0.68c
Ethnically white 97% 94% 0.53c
Prior use of protease inhibitor 84% 75% 0.45c
B Odds ratio 95% confidence interval p value
BAT1 (intron 10) 14.9 1.3–172 0.03
TNFA-1031 10.6 1.1–100 0.04
IL12B (3 UTR) 0.06 0.003–1.3 0.07
Height (cm) 1.4 1.13–1.8 0.002
aUnivariate analysis suggested height may affect NRTI-SN status (Panel A). Multivariate analysis comparing genotyping and
height between patients with definite NRTI-SN and patients who were NRTI-SN resistant or had late onset NRTI-SN yielded a
significant model (Panel B, p  0.0001).
bUnpaired t test.
c2 test.
was not significant (p  0.12) and no SNP examined was inde-
pendently associated with NRTI-SN status (p  0.05). Hence pa-
tients with late onset NRTI-SN are genetically distinct from those
with definite NRTI-SN. However, when late onset NRTI-SN pa-
tients were grouped with NRTI-SN-resistant patients, the model
was highly significant (p  0.001; Table 3B)
Inclusion of demographic details in the model
Clinical details including age,2,3 plasma lactate24 exposure
to protease inhibitors,25,26 and perhaps hepatitis C status27 have
previously been associated with NRTI-SN risk. Demographic
details of study patients (n  55, Table 4A) identify patient
height as the only feature associated with NRTI-SN status (p 
0.0001). Our logistic regression model for predicting NRTI-SN
risk was enhanced by adjusting for patient height (p  0.0001,
R2  0.54; Table 4B).
DISCUSSION
These data suggest a role for cytokine genotype in predict-
ing an individual’s risk of NRTI-SN following dNRTI expo-
sure. In this predominantly white population of Australian
adults with HIV infection, carriage of TNFA-1031*2 was more
common in patients with definite NRTI-SN (relative to control
donors), suggesting this allele marks susceptibility to NRTI-
SN. In contrast, carriage of IL12B (3 UTR)*2 was common in
NRTI-SN-free patients (compared with controls), suggesting
carriers of this allele are relatively protected from NRTI-SN.
TNFA-1031*2 was the allele most strongly associated with
NRTI-SN status and was overrepresented among patients with
definite NRTI-SN compared with control populations. It is not
currently clear whether carriage of this allele affects TNF-
production. However, TNF- is known to play a role in HIV-
associated neurological disease, including peripheral neuropa-
thy.7,8 TNFA-1031*2 occurs in a TNFA haplotype associated
with Behcet’s disease,28 a condition associated with local in-
creases in TNF-.29 Further, alleles at several loci upstream of
TNFA (including TNFA-1031) associate with poor control of
HIV viremia30 and with HIV-associated lipodystrophy.31
Therefore, the association between TNFA-1031*2 and NRTI-
SN following dNRTI exposure is biologically plausible and
consistent with findings from other disease states.
TNFA-308*2 and BAT1(intron 10)*2 were weakly associ-
ated with NRTI-SN status in this cohort (p  0.1), but emerged
as significant in the multivariate analysis. In whites, these al-
leles mark carriage of the 8.1 haplotype (HLA-A1, B8, DR3),
which has been linked with multiple immunopathological con-
ditions, including rapid progression to AIDS.32 BAT1 (intron
10)*2 is a more specific marker of the 8.1 haplotype than
TNFA-308*2.14 TNFA-308*2 has been associated with in-
creased TNF- production, but this finding is controversial.33
The allele also associates with an increased risk of HIV de-
mentia6 and a poorer outcome in infectious diseases including
cerebral malaria in Africans.34 However, the TNF block hap-
lotype containing TNFA-308*2 in Africans is highly conserved
and matches that of the white 8.1 haplotype,35 so it is not valid
to associate these phenotypes with any single allele.
The clear effect of TNFA-1031*2 on NRTI-SN suggests
TNF block haplotypes containing this allele also affect NRTI-
SN. Using 19 polymorphisms, we defined 17 haplotypes in this
region that account for around 90% of control donors in the
Western Australian population.15 We plan to examine haplo-
typic associations with NRTI-SN using these protocols, as a
polymorphism shared by haplotypes associated with NRTI-SN
in different ethnic populations is more likely to contribute to
pathogenesis. TNFA-1031*2 is found in five conserved MHC
haplotypes (unpublished observations).
Our data also suggest a role for the IL12B genotype in NRTI-
SN. IL12B(3 UTR)*2 was more common in patients who were
NRTI-SN resistant compared with controls or those with NRTI-
SN, suggesting a protective role for this allele. We have also
found IL12B (3 UTR)*2 is rare in HIV patients who experi-
ence immune reconstitution disease associated with previous
herpes virus infections following ART.5 In healthy donors, car-
riage of allele 2 associates with elevated IL-12p70 synthesis by
blood monocytes stimulated in vitro.36 Hence, a role for IL-12B
alleles in NRTI-SN warrants investigation in a larger cohort.
We examined polymorphisms in other genes previously as-
sociated with the immunopathology of HIV-related and other
infectious diseases, including IL1A,18,32 IL1B,32 IL4,37 IL6,21
IL10,38 IL10R1,23 IL18,39 and HSPA1B.13 We found no asso-
ciations between alleles of these genes and NRTI-SN. Future
studies will include other ethnicities.
Patients who developed neuropathy after more than 6 months
on a dNRTI had genotypes similar to those who were NRTI-
SN resistant. There is no objective method of differentiating
NRTI-SN from neuropathy due to HIV itself,2 with the diag-
nosis of NRTI-SN resting on the temporal relationship of symp-
tom onset to dNRTI exposure. NRTI-SN was the dose-limiting
toxicity in early clinical trials of all dNRTIs, and was found to
be universal given sufficient doses of ddC.2 Hence patients who
are not genetically predisposed to NRTI-SN may develop neu-
ropathy following sufficient dNRTI exposure.
Peripheral sensory nerves are supported by active trans-
port of essential compounds down long processes from the
dorsal root ganglia. This highly energy-dependent process
would be vulnerable to mitochondrial toxins such as dNR-
TIs. This may be most apparent in taller patients, as they have
an increased risk of various peripheral neuropathies.16,40
Height was associated with NRTI-SN in this cohort. A model
including cytokine genotype and height was strongly associ-
ated with NRTI-SN status, supporting our hypothesis that the
host inflammatory response is also important in NRTI-SN
pathogenesis.
In conclusion, we have developed a model to predict NRTI-
SN based on a patient’s height and cytokine genotype in an
Australian cohort. Following confirmation in larger cohorts
from ethnically distinct populations, this has the potential to fa-
cilitate more rational selection of ART regimens.
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